Epratuzumab decreases disease activity and steroid use in patients with moderate and severe flaring systemic lupus erythematosis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1645, 2008-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab: Severe disease exacerbation in patients with systemic lupus erythematosus and anti-phospholipid syndrome: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1238, 2009-01 ,pp. : 30-30

Adis International

Access to resources Recommend Favorite

Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease

By Plosker Greg L.   Lyseng-Williamson Katherine A.  

PharmacoEconomics, Vol. 23, Iss. 2, 2005-01 ,pp. : 193-206

Adis International

Access to resources Recommend Favorite

Memantine: A Review of its Use in Moderate to Severe Alzheimer's Disease

By McKeage Kate  

CNS Drugs, Vol. 23, Iss. 10, 2009-10 ,pp. : 881-897

Adis International

Access to resources Recommend Favorite

Cognitive enhancers provide some benefits in patients with moderate to severe Alzheimer's disease

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 4, 2011-04 ,pp. : 9-15

Adis International

Access to resources Recommend Favorite

Teduglutide induces remission in patients with moderate-to-severe Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1541, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite